

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hospital Corporation of China Limited

弘和仁愛醫療集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3869)

**ANNOUNCEMENT OF
(1) CHANGE OF DIRECTORS
(2) CHANGE OF CHAIRMAN OF THE BOARD
(3) CHANGE OF CHIEF EXECUTIVE OFFICER
(4) CHANGE IN COMPOSITION OF BOARD COMMITTEES
AND
(5) CHANGE OF AUTHORISED REPRESENTATIVE**

The Board hereby announces that with effect from June 23, 2020:

- (1) Mr. SHAN Guoxin has resigned as an executive Director, the Chief Executive Officer, a member of the Remuneration Committee and an Authorised Representative;
- (2) Mr. ZHAO John Huan has resigned as a non-executive Director, the chairman of the Board and the chairman of the Nomination Committee;
- (3) Mr. LI Peng has resigned as a non-executive Director and a member of the Audit Committee;
- (4) Mr. SU Zhiqiang has been appointed as an executive Director, a member of the Remuneration Committee and an Authorised Representative;
- (5) Mr. CHEN Shuai has been appointed as a non-executive Director, the chairman of the Board, the acting Chief Executive Officer and the chairman of the Nomination Committee; and
- (6) Ms. SHI Wenting has been appointed as a non-executive Director and a member of the Audit Committee.

RESIGNATION OF EXECUTIVE DIRECTOR, NON-EXECUTIVE DIRECTORS, CHAIRMAN OF THE BOARD, CHIEF EXECUTIVE OFFICER, CHAIRMAN OF NOMINATION COMMITTEE, MEMBER OF REMUNERATION COMMITTEE, MEMBER OF AUDIT COMMITTEE AND AUTHORISED REPRESENTATIVE

The board (the “**Board**”) of directors (the “**Directors**” and each a “**Director**”) of Hospital Corporation of China Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) hereby announces that with effect from June 23, 2020, (i) Mr. SHAN Guoxin (“**Mr. Shan**”) has resigned as an executive Director, the chief executive officer of the Company (“**Chief Executive Officer**”), a member of the remuneration committee of the Company (“**Remuneration Committee**”) and an authorised representative of the Company (“**Authorised Representative**”) under Rule 3.05 of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**HKEX**”) for personal development reasons; (ii) Mr. ZHAO John Huan (“**Mr. Zhao**”) has resigned as a non-executive Director, the chairman of the Board and the chairman of the nomination committee of the Company (“**Nomination Committee**”) due to work arrangements; and (iii) Mr. LI Peng (“**Mr. Li**”) has resigned as a non-executive Director and a member of the audit committee of the Company (“**Audit Committee**”) due to work arrangements.

Each of Mr. Shan, Mr. Zhao and Mr. Li has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation that needs to be brought to the attention of the shareholders of the Company.

The Board would like to express its sincere gratitude to Mr. Shan, Mr. Zhao and Mr. Li for their contributions to the development of the Group.

APPOINTMENT OF EXECUTIVE DIRECTOR, NON-EXECUTIVE DIRECTORS, CHAIRMAN OF THE BOARD, ACTING CHIEF EXECUTIVE OFFICER, CHAIRMAN OF NOMINATION COMMITTEE, MEMBER OF REMUNERATION COMMITTEE, MEMBER OF AUDIT COMMITTEE AND AUTHORISED REPRESENTATIVE

The Board further announces that with effect from June 23, 2020, (i) Mr. SU Zhiqiang (“**Mr. Su**”) has been appointed as an executive Director, a member of the Remuneration Committee and an Authorised Representative; (ii) Mr. CHEN Shuai (“**Mr. Chen**”) has been appointed as a non-executive Director, the chairman of the Board, the acting Chief Executive Officer and the chairman of the Nomination Committee; and (iii) Ms. SHI Wenting (“**Ms. Shi**”) has been appointed as a non-executive Director and a member of the Audit Committee.

Set out below are the biographies of Mr. Su, Mr. Chen and Ms. Shi and other information to be disclosed pursuant to Rule 13.51(2) of the Listing Rules:

Mr. SU Zhiqiang

Mr. Su, aged 36, joined Hony Capital (a series of private equity investment funds, together with their respective management companies/general partners, “**Hony Capital**”) in 2017 and serves as the investment director of the private equity investment department, with a focus on coverage of healthcare related fields of investment. Mr. Su also serves as a director of Shanghai Weikang Investment Management Co., Ltd., a subsidiary of the Company, and a council member of Shanghai Yangsi Hospital, a hospital founded by Shanghai Weikang Investment Management Co., Ltd. Prior to joining Hony Capital, Mr. Su worked in the investment management department of China Minmetals Corporation from 2009 to 2011 and in the investment department of CITIC Private Equity Funds Management Co., Ltd. from 2011 to 2013. Mr. Su subsequently served as an investment director at Sino-Rock Investment Management Company Limited, which is affiliated to China Cinda Asset Management Co., Ltd. (HKEX Stock Code: 1359), from 2014 to 2017.

Mr. Su obtained his bachelor's degree in financial engineering from Shandong University in June 2006, and a master's degree in finance from the Central University of Finance and Economics in June 2009.

Mr. Su has entered into a service contract with the Company regarding his appointment as an executive Director for an initial term of 3 years, during which he shall be subject to retirement and re-election in accordance with the memorandum and articles of association of the Company (the "Articles"). Accordingly, Mr. Su will only hold office until the first general meeting of the Company after his appointment and shall then be eligible for re-election at that general meeting, and thereafter subject to retirement by rotation at least once every three years at the annual general meeting of the Company in accordance with the Articles.

Mr. Su will not receive any remuneration for acting as an executive Director.

Mr. CHEN Shuai

Mr. Chen, aged 46, has extensive experience in investment management, supplier management and retail business. He joined Hony Capital in 2003 and has served as a managing director of Hony Capital since 2011. Mr. Chen also currently serves as the deputy general manager of the private equity investment department and a member of the private equity business steering committee of Hony Capital, as well as general manager of Hony Capital's Shanghai platform. Prior to joining Hony Capital, Mr. Chen was the senior financial manager of Wumart Stores, Inc., general manager of the vendor management department of Beijing Jiahe Group (北京家和集團), and senior investment manager of the investment management department and urban strategic circulation department of D'Long International Strategic Investment Company.

Mr. Chen is currently a non-executive director of China Rongzhong Financial Holdings Company Limited (HKEX Stock Code: 3963), a non-executive director of Century Ginwa Retail Holdings Limited (HKEX Stock Code: 162) and a director of Shanghai Chengtou Holding Co., Ltd. (Shanghai Stock Exchange Stock Code: 600649). He was a director of Shanghai Environment Group Co., Ltd. (Shanghai Stock Exchange Stock Code: 601200) from February 2017 to September 2019. Mr. Chen is also a member of the 11th Finance Sector Youth Union (青聯金融界別) of Shanghai and the 7th Merger and Reorganization Committee (併購重組委) of the China Securities Regulatory Commission.

Mr. Chen obtained his bachelor's degree in economics from Beijing Forestry University in 1997, and a Master of Business Administration from the China Europe International Business School in 2010.

Mr. Chen has entered into an appointment letter with the Company regarding his appointment as a non-executive Director for an initial term of 3 years, during which he shall be subject to retirement and re-election in accordance with the Articles. Accordingly, Mr. Chen will only hold office until the first general meeting of the Company after his appointment and shall then be eligible for re-election at that general meeting, and thereafter subject to retirement by rotation at least once every three years at the annual general meeting of the Company in accordance with the Articles.

Mr. Chen will only serve as the acting Chief Executive Officer until the Board appoints a new Chief Executive Officer. The Board is in the course of identifying suitable candidate(s) to fill the position of Chief Executive Officer and believes that the appointment of Mr. Chen will ensure the normal operations of the Company in the meantime and is in the interests of the Company and its shareholders as a whole. The Company will issue further announcement(s) as and when appropriate.

Mr. Chen will not receive any remuneration for acting as a non-executive Director and acting Chief Executive Officer.

Ms. SHI Wenting

Ms. Shi, aged 31, is currently the vice president in the consumption and advanced manufacturing investment department of Legend Holdings Corporation (HKEX Stock Code: 3396) (“**Legend Holdings**”). Ms. Shi joined Legend Holdings in 2016 and has served as the investment manager of the healthcare service investment department, investment manager and vice president of the innovative consumption and services investment department, and vice president of the consumption and advanced manufacturing investment department. Prior to joining Legend Holdings, Ms. Shi served as an analyst of the investment banking department of First Capital Investment Banking Co., Ltd (previously known as J.P. Morgan First Capital Securities Co., Ltd).

Ms. Shi obtained her bachelor’s degree in business administration and master’s degree in accounting from Tsinghua University in 2011 and 2013, respectively.

Ms. Shi has entered into an appointment letter with the Company regarding her appointment as a non-executive Director for an initial term of 3 years, during which she shall be subject to retirement and re-election in accordance with the Articles. Accordingly, Ms. Shi will only hold office until the first general meeting of the Company after her appointment and shall then be eligible for re-election at that general meeting, and thereafter subject to retirement by rotation at least once every three years at the annual general meeting of the Company in accordance with the Articles.

Ms. Shi will not receive any remuneration for acting as a non-executive Director.

As at the date of this announcement, Mr. Su, Mr. Chen and Ms. Shi (i) do not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) do not hold any position in the Company or members of the Group other than those disclosed above; and (iii) do not have any relationship with any Directors, senior management, or substantial or controlling shareholders (as respectively defined in the Listing Rules) of the Company.

Save as disclosed above, there is no further information relating to the appointments of Mr. Su, Mr. Chen and Ms. Shi that needs to be disclosed pursuant to any of the requirements under Rule 13.51(2) of the Listing Rules.

The Board would like to express its warmest welcome to Mr. Su, Mr. Chen and Ms. Shi on their appointments.

By order of the Board
Hospital Corporation of China Limited
Chen Shuai
Chairman

Beijing, China, June 23, 2020

As at the date of this announcement, the Directors of the Company are Mr. LU Wenzuo and Mr. SU Zhiqiang being the executive Directors; Mr. CHEN Shuai, Ms. SHI Wenting, Ms. LIU Lu and Ms. WANG Nan being the non-executive Directors; and Mr. DANG Jinxue, Mr. SHI Luwen and Mr. ZHOU Xiangliang being the independent non-executive Directors.